Download PDF
Synlett 2018; 29(10): 1346-1350
DOI: 10.1055/s-0037-1610127
letter
© Georg Thieme Verlag Stuttgart · New York

A Different Approach to the EGFR Inhibitor Gefitinib Involving Solid-Phase Synthesis

André Sequeira
a   LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal   Email: luisa_carvalho@campus.fct.unl.pt
,
Ana Lourenço
a   LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal   Email: luisa_carvalho@campus.fct.unl.pt
,
Luísa Maria Ferreira
a   LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal   Email: luisa_carvalho@campus.fct.unl.pt
,
Paula Sério Branco
a   LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal   Email: luisa_carvalho@campus.fct.unl.pt
,
Zita Mendes
b   Hovione FarmaCiencia SA, R&D, Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal
,
Nuno M. T. Lourenço
b   Hovione FarmaCiencia SA, R&D, Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal
,
Margarida Figueiredo
b   Hovione FarmaCiencia SA, R&D, Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal
,
Luísa C. R. Carvalho  *
a   LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal   Email: luisa_carvalho@campus.fct.unl.pt
› Author AffiliationsThis work was supported by the Associated Laboratory for Sustainable Chemistry - Clean Processes and Technologies LAQV, which is financed by national funds from FCT/MEC(UID/QUI/50006/2013) and co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007265). The NMR spectrometers are part of The National NMR Facility, supported by Fundação para a Ciência e Tecnologia (RECI/BBB-BQB/0230/2012). Moreover, the authors would like to thank Hovione FarmaCiencia SA for financial support.

Further Information

Publication History

Received: 20 February 2018

Accepted after revision: 30 March 2018

Publication Date:
09 May 2018 (online)

    Permissions and Reprints All articles of this category


Abstract

An efficient solid-phase synthesis approach is here reported for the first time to prepare the EGFR inhibitor Gefitinib. The five-step synthetic strategy used FMP resin as the solid support, and FTIR and colorimetric assays were used to track the reaction’s progress. Gefitinib was obtained with an overall yield of 40%.

Key words

solid-phase synthesis - Gefitinib - quinazoline - FMP resin - colorimetric assays

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1610127.
  • Supporting Information
 

  • References and Notes

  • 1 Dhillon S. Target. Oncol. 2015; 10: 153
    CrossrefPubMedSearch in Google Scholar
  • 2 Liu Y. Ramirez J. House L. Ratain MJ. Drug Metab. Dispos. 2010; 38: 32
    CrossrefPubMedSearch in Google Scholar
  • 3 Lynch TJ. Bell DW. Sordella R. Gurubhagavatula S. Okimoto RA. Brannigan BW. Harris PL. Haserlat SM. Supko JG. Haluska FG. Louis DN. Christiani DC. Settleman J. Haber DA. N. Engl. J. Med. 2004; 350: 2129
    CrossrefPubMedSearch in Google Scholar
  • 4 Kris MG. Natale RB. Herbst RS. Lynch TJ. Prager D. Belani CP. Schiller JH. Kelly K. Spiridonidis H. Sandler A. Albain KS. Cella D. Wolf MK. Averbuch SD. Ochs JJ. Kay AC. JAMA, J. Am. Med. Assoc. 2003; 290: 2149
    CrossrefPubMedSearch in Google Scholar
  • 5 Gibson KH. WO 1996033980, 1996
    PubMed
  • 6 Knesl P. Roseling D. Jordis U. Molecules 2006; 11: 286
    CrossrefPubMedSearch in Google Scholar
  • 7 Gilday JP. Welham JW. WO 2005023783, 2005
    PubMed
  • 8 Zhang X. Xizhou L. WO 2015188318, 2015
    PubMed
  • 9 Aggarwal AK. Jain AK. Chidambaram VS. Wadhwa LA. WO 2010076810, 2010
    PubMed
  • 10 Chao W. Juanfang X. Yajun K. Yan L. CN 105503748, 2016
    PubMed
  • 11 Gordon K. Balasubramanian S. J. Chem. Technol. Biotechnol. 1999; 74: 835
    CrossrefSearch in Google Scholar
  • 12 Eifler-Lima VL. Graebin CS. Uchoa FD. Duarte PD. Correa AG. J. Braz. Chem. Soc. 2010; 21: 1401
    CrossrefSearch in Google Scholar
  • 13 Chen ZP. Hemmasi B. Biol. Chem. Hoppe-Seyler 1993; 374: 1057
    CrossrefPubMedSearch in Google Scholar
  • 14 Deadman BJ. Hopkin MD. Baxendale IR. Ley SV. Org. Biomol. Chem. 2013; 11: 1766
    CrossrefPubMedSearch in Google Scholar
  • 15 Porta R. Benaglia M. Puglisi A. Org. Process Res. Dev. 2016; 20: 2
    CrossrefSearch in Google Scholar
  • 16 Antonow D. Graebin CS. Eifler-Lima VL. J. Braz. Chem. Soc. 2004; 15: 782
    CrossrefSearch in Google Scholar
  • 17 Carvalho LR. Corvo MC. Enugala R. Marques MM. B. Cabrita EJ. Magn. Reson. Chem. 2010; 48: 323
    CrossrefPubMedSearch in Google Scholar
  • 18 Power WP. In Annual Reports on NMR Spectroscopy . Academic Press; London: 2003: 261
    Search in Google Scholar
  • 19 Gaggini F. Porcheddu A. Reginato G. Rodriquez M. Taddei M. J. Comb. Chem. 2004; 6: 805
    CrossrefPubMedSearch in Google Scholar
  • 20 Molchanova N. Hansen PR. Franzyk H. Molecules 2017; 22
    PubMed
  • 21 Verlander M. Int. J. Pept. Res. Ther. 2007; 13: 75
    CrossrefSearch in Google Scholar
  • 22 Lönnberg H. Bioconjug. Chem. 2009; 20: 1065
    CrossrefPubMedSearch in Google Scholar
  • 23 Gil C. Brase S. J. Comb. Chem. 2009; 11: 175
    CrossrefPubMedSearch in Google Scholar
  • 24 Georgiadis TM. Baindur N. Player MR. J. Comb. Chem. 2004; 6: 224
    CrossrefPubMedSearch in Google Scholar
  • 25 Abreu PM. Branco PS. J. Braz. Chem. Soc. 2003; 14: 675
    CrossrefSearch in Google Scholar
  • 26 Nandy JP. Prakesch M. Khadem S. Reddy PT. Sharma U. Arya P. Chem. Rev. 2009; 109: 1999
    CrossrefPubMedSearch in Google Scholar
  • 27 Pendri A. Dodd DS. Chen J. Cvijic ME. Rang LY. Baska RA. Carlson KE. Burford NT. Sun CQ. Ewing WR. Gerritz SW. ACS Comb. Sci. 2012; 14: 197
    CrossrefPubMedSearch in Google Scholar
  • 28 Kwak SH. Kim MJ. Lee SD. You H. Kim YC. Ko H. ACS Comb. Sci. 2015; 17: 60
    CrossrefPubMedSearch in Google Scholar
  • 29 Shannon SK. Barany G. J. Comb. Chem. 2004; 6: 165
    CrossrefPubMedSearch in Google Scholar
  • 30 Boas U. Mirsharghi S. Org. Lett. 2014; 16: 5918
    CrossrefPubMedSearch in Google Scholar
  • 31 Blackburn C. In Solid-Phase Synthesis: A Practical Guide . Marcel Dekker; New York: 2000: 198
    Search in Google Scholar
  • 32 Chandregowda V. Rao GV. Reddy GC. Heterocycles 2007; 71: 39
    CrossrefSearch in Google Scholar
  • 33 N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, Gefitinib (1) A solution of TFA 10% in dry DCM was added to the functionalized FMP resin 8 (400 mg, 0.255 mmol). The mixture was stirred for 24 h at room temperature. The resin was filtered and washed with DCM, MeOH/THF (1:1) and H2O/THF (1:1), and the combined phases were collected and evaporated. The crude was resuspended in DCM, and a 2 M NaOH solution was added to neutralize the removed compound. The organic phase was dried over Na2SO4 and evaporated to dryness. Gefitinib (1) was obtained as a yellow solid (50 mg, 0.112 mmol, 44%, crude, HPLC purity: >99%); mp 186–188 oC. 1H NMR (400 MHz, CDCl3): δ = 8.65 (s, 1 H, ArH-2), 7.92–7.91 (m, 1 H, ArH-13), 7.59–7.57 (m, 1 H, ArH-16), 7.53 (br s, 1 H, NH), 7.24 (s, 1 H, ArH-7), 7.18–7.13 (m, 2 H, ArH-10 and ArH-17), 4.20 (t, J = 6.5 Hz, 2 H, H-18), 3.99 (s, 3 H, OCH3), 3.77 (m, 4 H, H-22 and H-22′), 2.65–2.55 (m, 6 H, H-21, H-21′ and H-20), 2.15–2.12 (m, 2 H, H-19). 13C NMR (400 MHz, CDCl3): δ = 156.4 (C-4), 155.3 (C-8), 153.6 (C-2), 149.0 (C-9), 147.6 (C-5), 135.6 (C-12), 124.3 (C-16), 122.2 (C-17), 121.8 (C-15), 116.8 (C-13), 109.1 (C-6), 108.1 (C-10), 101.4 (C-7), 67.7 (C-18), 66.6 (C-22 and C-22′), 56.3 (OCH3), 55.5 (C-20), 53.7 (C-21 and C-21′), 25.9 (C-19). FTIR: νmax (KBr): 3400 (m, N–H stretch), 2957, 2809 (m, C–H stretch (aliphatic)), 1625, 1579 (w, C–C stretch (Ar)), 1501 (w, N–H bend), 1219 (m, C–F stretch (Ar)) cm–1.